問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3348Cases

2023-01-30 - 2026-01-26

Phase II

Active
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  • Condition/Disease

    Obesity

  • Test Drug

    皮下注射劑

Participate Sites
4Sites

Recruiting4Sites

2023-07-31 - 2031-02-01

Phase III

Active
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)

  • Condition/Disease

    Non-Small Cell Lung Cancer (NSCLC)

  • Test Drug

    sotorasib (AMG 510)Pembrolizumab

Participate Sites
7Sites

Recruiting7Sites

2023-03-01 - 2029-05-01

Phase III

Active
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

  • Condition/Disease

    Small Cell Lung Cancer (SCLC)

  • Test Drug

    tarlatamab (AMG 757)

Participate Sites
5Sites

Recruiting5Sites

2024-09-24 - 2029-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-05-02 - 2026-01-17

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-05-15 - 2030-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-10-01 - 2027-08-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-12-01 - 2029-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-11-01 - 2028-09-30

Phase I

Active
An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors

  • Condition/Disease

    Advanced Tumors

  • Test Drug

    tablets

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2021-12-31 - 2026-12-31

Phase III

Active
A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)

  • Condition/Disease

    FSGS

  • Test Drug

    膠囊劑

Participate Sites
8Sites

Recruiting8Sites

1 116 117 118 119 120 335
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB